Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Little Green PharmaASX:LGP +4.00% EV-to-EBITDA is 23.93 as of Jul. 29, 2026. The stock has 3 warning signs investors should review. Among 744 Drug Manufacturers companies, Little Green Pharma ranks worse than 74.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Little Green Pharma's enterprise value is A$65.07 Mil.
Little Green Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$2.72 Mil. Therefore, Little Green Pharma's EV-to-EBITDA for today is 23.93.
The historical rank and industry rank for Little Green Pharma's EV-to-EBITDA or its related term are showing as below:
ASX:LGP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -60.12 Med: -7.27 Max: 23.93
Current: 23.93
During the past 7 years, the highest EV-to-EBITDA of Little Green Pharma was 23.93. The lowest was -60.12. And the median was -7.27.
ASX:LGP's EV-to-EBITDA is ranked worse than 74.46% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs ASX:LGP: 23.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Little Green Pharma (ASX:LGP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Little Green Pharma's PE Ratio (TTM) for today is calculated as:
Little Green Pharma's share price for today is A$0.078.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Little Green Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Little Green Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Little Green Pharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Little Green Pharma's EV-to-EBITDA falls into.
Little Green Pharma's current Enterprise Value is A$65.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Little Green Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$2.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Little Green Pharma (ASX:LGP) has a EV-to-EBITDA of 23.93 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Little Green Pharma. According to the industry distribution chart, Little Green Pharma ranks #554 out of 744 companies in the Drug Manufacturers industry, placing it in the top 74.5%.
Is Little Green Pharma's EV-to-EBITDA too high?
Little Green Pharma's current EV-to-EBITDA is 23.93. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Little Green Pharma's value of 23.93 is 84.4% above this industry median. Based on the distribution chart, Little Green Pharma ranks #554 out of 744 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Little Green Pharma's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Little Green Pharma ranks #554 out of 744 companies for EV-to-EBITDA. This places Little Green Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Little Green Pharma's value of 23.93 is 84.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Little Green Pharma's current EV-to-EBITDA of 23.93 is 84.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Little Green Pharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Little Green Pharma's current EV-to-EBITDA is 23.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.18, compared to a current price of A$0.08 — trading 56.7% below its estimated fair value. The current EV-to-EBITDA is 23.93 and 84.4% above the Drug Manufacturers industry median of 12.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current EV-to-EBITDA is 23.93 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LGP has been successfully added to your 
